Mark Botti is partner with Baker Botts, based in the firm’s Washington office. She advises clients and represents them on the full spectrum of antitrust matters, including government investigations, mergers and acquisitions, joint ventures, government and private litigation, and competition policy matters. His work has spanned all sectors of the economy, including healthcare, managed care and health information technology; financial services, including electronic payment systems; intellectual property and high technology matters; forestry products; consumer products; national defense; media and entertainment; and insurance. Mark Botti served for 13 years at the U.S. Department of Justice in various litigation and leadership positions within the Antitrust Division. He litigated and supervised complex antitrust matters, mergers and acquisitions, monopolization cases and joint ventures. He consulted regularly with international antitrust enforcement authorities on investigatory matters and on the development of their merger and other antitrust regulations and practices. Mark Botti was the Division official who directly oversaw the extensive hearings held by the Division and the Federal Trade Commission on healthcare during the years 2004-2005, as well as drafted the agency’s joint seminal report, "Improving Health Care: A Dose of Competition."
79
A Federal Trade Commission (FTC) settlement filed last week with merging pharmaceutical manufacturers re-opens a seemingly foreclosed antitrust path to clearance for parties pursuing non-horizontal mergers and acquisitions where antitrust considerations play a significant role. Background (...)
279
On February 25, 2008, UnitedHealth Group (United) and Sierra Health Services, Inc. (Sierra) announced that they would proceed with a merger whereby United will acquire all outstanding shares of Sierra in a transaction valued at $2.6 billion. Their statement came shortly after the United States (...)
